ホーム › アトピー性皮膚炎（湿疹） › ミシガン州
ミシガン州におけるアトピー性皮膚炎（湿疹）の臨床試験
ミシガン州内の拠点で、アトピー性皮膚炎（湿疹）に関する14件の研究が参加者を募集しています。
ミシガン州内の都市
公式研究テキスト（英語）
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- David Fivenson, MD, Dermatology, PLLC- Site Number : 8400017, Ann Arbor
- Oakland Hills Dermatology- Site Number : 8400042, Auburn Hills
- Great Lakes Research Group - Bay City- Site Number : 8400052, Bay City
- 他3件
被験者募集中観察研究
12歳以上 · 全性別 · 2026/09/29更新 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Troy
被験者募集中第2相
18歳〜100歳 · 全性別 · 2026/09/28更新 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Auburn Hills
- Enveda Investigative Site, Bay City
- Enveda Investigative Site, Clinton Township
- 他1件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT07298395A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Detroit
- Investigational Site, Troy
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07003425Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- Derm Research Institute, PLC, Caledonia
被験者募集中観察研究
12歳〜89歳 · 全性別 · 2026/09/15更新 · NCT07645820A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- Revival Research Institute, LLC, Troy
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07223697FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Revival Research Institute, LLC, Troy
被験者募集中第1相健康なボランティア歓迎
18歳〜70歳 · 全性別 · 2026/07/22更新 · NCT06564389A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Waterford
被験者募集中第3相
6 Months – 11 Years · 全性別 · 2026/07/07更新 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Henry Ford Medical Center - New Center One /ID# 263522, Detroit
被験者募集中第3相
18歳〜63歳 · 全性別 · 2026/07/06更新 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Michigan Center for Research Company, Clarkston
- MI Skin Innovations, Northville
- Revival Research Institute LLC, Troy
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/04更新 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7066, Auburn Hills
- Galderma Investigational Site 7071, Caledonia
- Galderma Investigational Site 7108, Grandville
- 他1件
被験者募集中観察研究
12歳以上 · 全性別 · 2026/03/13更新 · NCT06988605Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
- University of Michigan, Ann Arbor
被験者募集中健康なボランティア歓迎
10歳〜55歳 · 全性別 · 2025/11/25更新 · NCT06300697Ethnic Differences in Mechanisms of Action of Dupilumab
- University of Michigan, Ann Arbor
被験者募集中第4相
18歳以上 · 全性別 · 2025/11/06更新 · NCT05268107A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
- University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor
被験者募集中第2相
18歳〜75歳 · 全性別 · 2025/01/24更新 · NCT06524635ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。